• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

CIB2 Is a Novel Endogenous Repressor of Atrial Remodeling
CONCLUSIONS: Our data suggest that CIB2 represents a novel endogenous and atrial-enriched regulator that protects against atrial remodeling and AF under stress conditions. Therefore, CIB2 may represent a new potential target for treating AF.PMID:37128899 | DOI:10.1161/CIRCULATIONAHA.122.062660
Source: Circulation - May 2, 2023 Category: Cardiology Authors: Yihui Wang Jizheng Wang Ling Shi Xiuyu Chen Desheng Li Chen Cui Kai Yang Minjie Lu Jinhua Huang Lei Zhang Fei Li Jinxi Wang Biyi Chen Bin Wang Duane D Hall Zhenwei Pan Jiang Hong Long-Sheng Song Lei Song Shihua Zhao Source Type: research

Determinants of Incident Atherosclerotic Cardiovascular Disease Events Among Those With Absent Coronary Artery Calcium: Multi-Ethnic Study of Atherosclerosis
Conclusions: Current cigarette smoking, diabetes mellitus, and hypertension are independently associated with incident ASCVD over 16-year follow-up among those with CAC=0. Family history of premature ASCVD may be associated with ASCVD risk among women only.PMID:34879218 | DOI:10.1161/CIRCULATIONAHA.121.056705
Source: Circulation - December 8, 2021 Category: Cardiology Authors: Mahmoud Al Rifai Michael J Blaha Vijay Nambi Steven J C Shea Erin D Michos Roger S Blumenthal Christie M Ballantyne Moyses Szklo Philip Greenland Michael D Miedema Khurram Nasir Jerome I Rotter Xiuqing Guo Jie Yao Wendy S Post Salim S Virani Source Type: research

Use of Genetic Variants Related to Antihypertensive Drugs to Inform on Efficacy and Side Effects.
CONCLUSIONS: Genetic variants can be used to explore the efficacy and side effects of antihypertensive medications. The identified potential effect of nondihydropyridine CCBs on diverticulosis risk could have clinical implications and warrants further investigation. PMID: 31234639 [PubMed - as supplied by publisher]
Source: Circulation - June 24, 2019 Category: Cardiology Authors: Gill D, Georgakis MK, Koskeridis F, Jiang L, Feng Q, Wei WQ, Theodoratou E, Elliott P, Denny JC, Malik R, Evangelou E, Dehghan A, Dichgans M, Tzoulaki I Tags: Circulation Source Type: research

A Novel Role for the AnxA1-Fpr2/ALX Signaling Axis as a Key Regulator of Platelet Function to Promote Resolution of Inflammation.
Conclusions: AnxA1 affords protection by altering the platelet phenotype in cerebral I/RI from pro-pathogenic to regulatory, and reducing the propensity for platelets to aggregate and cause thrombosis by affecting integrin (αIIbβ3) activation, a previously unknown phenomenon. Thus, our data reveal a novel multi-faceted role for AnxA1 to act both as a therapeutic and a prophylactic drug via its ability to promote endogenous pro-resolving, anti-thrombo-inflammatory circuits in cerebral I/RI. Collectively, these results further advance our knowledge and understanding in the field of platelet and Resolution Biology. PMI...
Source: Circulation - June 2, 2019 Category: Cardiology Authors: Senchenkova EY, Ansari J, Becker F, Vital SA, Al-Yafeai Z, Sparkenbaugh EM, Pawlinski R, Stokes KY, Carroll JL, Dragoi AM, Qin CX, Ritchie RH, Sun H, Cuellar-Saenz HH, Rubinstein MR, Han YW, Orr AW, Perretti M, Granger DN, Gavins FNE Tags: Circulation Source Type: research

A Multimodality Strategy for Cardiovascular Risk Assessment: Performance in Two Population-Based Cohorts.
Conclusions -Among adults without known CVD, a novel multimodality testing strategy using ECG-LVH, CAC, NT-proBNP, hs-cTnT and hs-CRP significantly improved global CVD and ASCVD risk assessment. PMID: 28360032 [PubMed - as supplied by publisher]
Source: Circulation - March 30, 2017 Category: Cardiology Authors: de Lemos JA, Ayers CR, Levine BD, deFilippi CR, Wang TJ, Hundley WG, Berry JD, Seliger SL, McGuire DK, Ouyang P, Drazner MH, Budoff MJ, Greenland P, Ballantyne CM, Khera A Tags: Circulation Source Type: research

Utility of Non-Traditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 ACC/AHA Cholesterol Guidelines.
CONCLUSIONS: -In this generally low-risk population sample, a large proportion of ASCVD events occurred among adults with a 10-yr. cPCE risk <7.5%. We found that the CAC, hsCRP, FH and ABI recommendations by the ACC/AHA cholesterol guidelines (Class IIB) identify small subgroups of asymptomatic population with <7.5% 10 yr. cPCE but with observed ASCVD event rates higher than 7.5% who may warrant statin therapy considerations. PMID: 26224808 [PubMed - as supplied by publisher]
Source: Circulation - July 29, 2015 Category: Cardiology Authors: Yeboah J, Polonsky TS, Young R, McClelland RL, Delaney JC, Dawood F, Blaha MJ, Miedema MD, Sibley CT, Carr JJ, Burke GL, Goff DC, Psaty BM, Greenland P, Herrington DM Tags: Circulation Source Type: research

Dyslipidemia, Coronary Artery Calcium, and Incident Atherosclerotic Cardiovascular Disease: Implications for Statin Therapy from the Multi-Ethnic Study of Atherosclerosis.
CONCLUSIONS: CAC may have the potential to help match statin therapy to absolute CVD risk. Across the spectrum of dyslipidemia, event rates similar to secondary prevention populations were observed for patients with CAC>=100. PMID: 24141324 [PubMed - as supplied by publisher]
Source: Circulation - October 20, 2013 Category: Cardiology Authors: Martin SS, Blaha MJ, Blankstein R, Agatston AS, Rivera JJ, Virani SS, Ouyang P, Jones SR, Blumenthal RS, Budoff MJ, Nasir K Tags: Circulation Source Type: research